Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Nct04512345 treatment anaerobic bacterial infections tinidazole?

What is NCT04512345 studying, and how does tinidazole fit in?

NCT04512345 is a clinical trial studying treatment for anaerobic bacterial infections. Tinidazole is an anti-anaerobic antimicrobial (a nitroimidazole) that targets bacteria that grow without oxygen, which is why it is commonly used as part of therapy for anaerobic infections.

What types of anaerobic infections are tinidazole trials usually aimed at?

When tinidazole is used for “anaerobic bacterial infections,” trials typically focus on infections where anaerobes are a known cause, such as infections related to the mouth/dental area, intra-abdominal infections, and certain gynecologic infections. The exact infection type for NCT04512345 depends on the trial’s inclusion criteria.

How is tinidazole usually used for anaerobic infections (mechanism and practical use)?

Tinidazole works by damaging DNA in susceptible anaerobic microorganisms after the drug is activated under low-oxygen conditions. In clinical practice, it is often paired with other agents when broader coverage is needed (for example, when mixed aerobic and anaerobic bacteria may be involved), but the trial’s protocol determines whether tinidazole is used alone or with additional antibiotics.

What side effects do patients ask about with tinidazole?

Common tinidazole side effects generally include nausea, a metallic taste, headache, dizziness, and abdominal discomfort. Patients also commonly ask about alcohol interactions: many nitroimidazoles are associated with a disulfiram-like reaction risk when alcohol is consumed during treatment and for a period after the last dose.

Can the trial results apply to my specific anaerobic infection?

Your applicability depends on whether your infection matches the trial’s enrollment criteria (infection source, severity, organism susceptibility, and whether the study is testing tinidazole alone or in combination). If you share the trial’s infection indication (for example, dental, intra-abdominal, pelvic), the dosing strategy (if listed), or the study arm description, I can map how tinidazole is typically positioned for that scenario.

What to do next if you’re looking for the trial protocol details

If you paste the NCT04512345 “Conditions” section (or the trial’s intervention text), I can translate it into plain language—what infection it covers, whether tinidazole is the main drug, and how the study design likely compares regimens.

Sources

No source links were provided with the prompt, and I don’t have enough information here to reliably pull NCT04512345 details (e.g., the exact condition, intervention arms, or outcomes). If you provide the trial’s intervention text or a link, I can produce a precise, trial-specific answer.



Other Questions About Bacterial :

What specific bacterial strain is primarily targeted by tigecycline? How do bacterial efflux pumps affect tigecycline? What bacterial infections best respond to tigecycline combos? Are there specific bacterial infections where tigecycline's success rate is higher in combined treatments? Can you provide an example of a bacterial infection treated with tigecycline? In what types of bacterial infections is tigecycline most effective? How does bacterial resistance to tigecycline emerge?